Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials.
apolipoprotein C
fenofibrate
fibrate
meta-analysis
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
22 02 2019
22 02 2019
Historique:
entrez:
25
2
2019
pubmed:
25
2
2019
medline:
3
1
2020
Statut:
epublish
Résumé
This meta-analysis of randomised placebo-controlled clinical trials aimed to assess the effect of fenofibrate on apolipoprotein C-III (apo C-III), a key regulator of triglyceride metabolism. Randomised placebo-controlled trials investigating the impact of fenofibrate treatment on apo C-III levels were searched in PubMed-Medline, Scopus, Web of Science and Google Scholar databases from inception to 18 August 2017. Quantitative data synthesis was determined by a random-effects model and generic inverse variance method. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate glycaemic parameter confounders. Meta-analysis of 10 clinical trials involving 477 subjects showed fenofibrate therapy decreased apo C-III levels (weighted mean difference (WMD) -4.78 mg/dL, 95% CI -6.95 to -2.61, p<0.001; I This meta-analysis found that fenofibrate therapy significantly decreases apo C-III levels, an effect evident with both short-term treatment and doses less than 200 mg/day.
Identifiants
pubmed: 30798284
pii: bmjopen-2018-021508
doi: 10.1136/bmjopen-2018-021508
pmc: PMC6278807
doi:
Substances chimiques
Apolipoprotein C-III
0
Hypolipidemic Agents
0
Fenofibrate
U202363UOS
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e021508Informations de copyright
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: NK has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, Astra Zeneca, Boehringer Ingelheim, Elpen, MSD, Novartis, NovoNordisk, Sanofi and WinMedica. MB has served on speaker’s bureau and as an advisory board member for Amgen, Sanofi-Aventis and Lilly.
Références
Curr Pharm Des. 2013;19(17):3124-31
pubmed: 23317397
Clin Pharmacol Ther. 2003 Sep;74(3):236-44
pubmed: 12966367
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
Science. 2008 Dec 12;322(5908):1702-5
pubmed: 19074352
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):239-45
pubmed: 19910636
Atherosclerosis. 2013 Sep;230(1):110-20
pubmed: 23958262
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Cardiovasc Pathol. 2009 May-Jun;18(3):140-7
pubmed: 18436454
Vasc Health Risk Manag. 2008;4(5):991-1000
pubmed: 19183747
Arch Intern Med. 2002 Dec 9-23;162(22):2597-604
pubmed: 12456232
Diabetes Obes Metab. 2010 Sep;12(9):752-6
pubmed: 20649626
Atherosclerosis. 2016 Jun;249:36-43
pubmed: 27062408
Circulation. 2007 Jan 30;115(4):450-8
pubmed: 17190864
Atherosclerosis. 2007 Jan;190(1):106-13
pubmed: 16600250
Pharmacol Res. 2016 May;107:234-242
pubmed: 27025786
N Engl J Med. 2008 Nov 20;359(21):2195-207
pubmed: 18997196
J Am Coll Cardiol. 2017 Feb 21;69(7):789-800
pubmed: 28209220
Clin Cardiol. 2006 Jun;29(6):268-73
pubmed: 16796078
J Biol Chem. 1983 Aug 10;258(15):9086-92
pubmed: 6874679
Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):524-531
pubmed: 28605473
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Nat Rev Cardiol. 2017 Jul;14(7):401-411
pubmed: 28300080
Metabolism. 2016 May;65(5):609-622
pubmed: 27085770
PPAR Res. 2008;2008:132960
pubmed: 18288277
Diab Vasc Dis Res. 2008 Nov;5(4):319-35
pubmed: 18958843
N Engl J Med. 2015 Jul 30;373(5):438-47
pubmed: 26222559
Lancet. 2005 Nov 26;366(9500):1849-61
pubmed: 16310551
Pharmacol Res. 2015 Dec;102:63-70
pubmed: 26384444
Clin Sci (Lond). 2010 Feb 23;118(10):607-15
pubmed: 20047560
J Clin Pharmacol. 2005 May;45(5):504-13
pubmed: 15831773
BMC Med. 2017 Feb 3;15(1):22
pubmed: 28153024
Prog Mol Biol Transl Sci. 2014;121:217-66
pubmed: 24373239
Clin Ther. 2002 Oct;24(10):1614-26
pubmed: 12462290
J Lipid Res. 2011 Jun;52(6):1067-70
pubmed: 21421846
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Curr Vasc Pharmacol. 2011 Sep;9(5):531-2
pubmed: 21595629
N Engl J Med. 2014 Dec 4;371(23):2200-6
pubmed: 25470695
Pharmacol Res. 2016 Sep;111:163-179
pubmed: 27320045
Atherosclerosis. 2010 May;210(1):35-40
pubmed: 20005515
J Clin Endocrinol Metab. 2010 Feb;95(2):829-36
pubmed: 20061429
Atherosclerosis. 2011 Aug;217(2):492-8
pubmed: 21592479
Curr Med Res Opin. 2004 Aug;20(8):1197-207
pubmed: 15324522
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212
pubmed: 28473441
Sci Rep. 2015 May 13;5:9902
pubmed: 25970700
Physiol Res. 2015;64 Suppl 3:S331-40
pubmed: 26680666
Curr Ther Res Clin Exp. 2003 Jul;64(7):434-46
pubmed: 24944394
N Engl J Med. 2014 Jul 3;371(1):22-31
pubmed: 24941081
Curr Opin Lipidol. 2014 Feb;25(1):35-9
pubmed: 24345989
Eur Heart J Suppl. 2016 Apr 12;18(Suppl C):C2-C12
pubmed: 28533705
DNA Cell Biol. 2013 Apr;32(4):188-98
pubmed: 23448101
Clin Chem. 2008 Aug;54(8):1325-30
pubmed: 18556334
Curr Opin Cardiol. 2017 Jul;32(4):422-429
pubmed: 28362666
Atherosclerosis. 2015 May;240(1):284-96
pubmed: 25828270
J Clin Lipidol. 2015 Jul-Aug;9(4):498-510
pubmed: 26228667
J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
pubmed: 17264176
Pharmacol Res. 2016 Jan;103:236-52
pubmed: 26657419
Curr Med Chem. 2014;21(25):2892-901
pubmed: 24606516
Atheroscler Suppl. 2015 Sep;19:1-12
pubmed: 26315511
J Lipid Res. 2012 Nov;53(11):2443-9
pubmed: 22930812